The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease

Current Opinion in Infectious Diseases

Volumn 19, Issue 3, 2006, Pages 225-230

  Murphy, Timothy F ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

Airway inflammation; Bacteria; Chronic obstructive pulmonary disease

Indexed keywords

BACTERIAL ANTIGEN; CYTOKINE; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; BACTERIAL STRAIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EVALUATION; HAEMOPHILUS INFLUENZAE; HUMAN; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ADULT; BACTERIAL INFECTIONS; BRONCHOALVEOLAR LAVAGE FLUID; HAEMOPHILUS INFLUENZAE; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 33646697956     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000224815.89363.15     Document Type: Review

References (51)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4:1241-1243.
2. Global Initiative on Obstructive Lung Disease. Workshop Report, Global Strategy for Diagnosis, Management, and Prevention of COPD. Available from http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intld=989. [Accessed 26 December 2005].
3. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-1320.
4. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53:262-267.
5. Monso E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13:338-342.
6. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:343-348.
7. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997; 10:1137-1144.
8. Berenson CS, Murphy TF, Wrona CT, Sethi S. Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immun 2005; 73:2728-2735. The highly conserved P6 protein is a specific trigger to human macrophage inflammatory events with IL-8 and TNF-α as key effectors. P6 induces macrophage cytokines at the physiological concentration of 10 pg/ml, indicating these effects are likely to occur in vivo.
9. Shuto T, Xu H, Wang B, et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-1 kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A 2001; 98:8774-8779.
10. Di Stefano A, Caramori G, Ricciardolo FL, et al. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy 2004; 34:1156-1167.
11. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56:515-548.
12. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:26-33.
13. Barnes PJ, Cosio MG. Characterization of T lymphocytes in chronic obstructive pulmonary disease. PLoS Med 2004; 1:e20.
14. Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2005; 2:361-366; discussion 371-372.
15. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364:985-996.
16. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126:926-934.
17. Buhl R, Farmer SG. Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:83-93. An excellent review of approaches to drug therapy of COPD, including a summary of approaches to reducing pulmonary inflammation. Many of the approaches involve inhibition of mediators induced by bacterial antigens.
18. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084-1106.
19. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26:192-203.
20. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000. A state of the art review. Clin Microbiol Rev 2001; 14:336-363.
21. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002; 37:1s-2s.
22. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26:523-548. Consensus recommendations on the collection of exhaled breath condensates by an expert task force of the American Thoracic Society and European Respiratory Society.
23. Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999; 160:S21-S25.
24. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147:1126-1131.
25. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266-272.
26. Tsoumakidou M, Tzanakis N, Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med 2003; 97:863-871.
27. Simpson JL, Wood LG, Gibson PG. Inflammatory mediators in exhaled breath, induced sputum and saliva. Clin Exp Allergy 2005; 35:1180-1185.
28. Antczak A, Kharitonov SA, Montuschi P, et al. Inflammatory response to sputum induction measured by exhaled markers. Respiration 2005; 72:594-599.
29. Carpagnano GE, Foschino Barbaro MP, Cagnazzo M, et al. Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge. Chest 2005; 128:3159-3166.
30. Kips JC, Inman MD, Jayaram L, et al. The use of induced sputum in clinical trials. Eur Respir J Suppl 2002; 37:47s-50s.
31. Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur Respir J Suppl 2002; 37:3s-8s.
32. Effros RM, Su J, Casaburi R, et al. Utility of exhaled breath condensates in chronic obstructive pulmonary disease: a critical review. Curr Opin Pulm Med 2005; 11:135-139. A comprehensive, critical review of the value and the limitations of the analysis of exhaled breath condensates in COPD.
33. Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005; 99:1229-1240.
34. Kharitonov SA, Barnes PJ. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:191-199.
35. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295.
36. Stockley RA, Hill AT, Hill SL, Campbell EJ. Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency. Chest 2000; 117 (Suppl 1):291S-293S.
37. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14:1015-1022.
38. Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118:1557-1565.
39. Hurst JR, Wilkinson TM, Perera WR, et al. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005; 127:1219-1226. This study demonstrated a correlation between upper and lower airway inflammation in adults with COPD.
40. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004; 23:685-691.
41. Tsoumakidou M, Tzanakis N, Chrysofakis G, et al. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99:572-579.
42. Tsoumakidou M, Tzanakis N, Chrysofakis G, et al. Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 2005; 127:1911-1918.
43. Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25:640-646.
44. Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J 2005; 26:1009-1015.
45. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004.
46. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60:293-300.
47. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:71-78. [Epub ahead of print, 22 Sep 2005]. This study demonstrated that systemic inflammation is increased during exacerbations and that the presence of a sputum bacterial pathogen is associated with a greater degree of airway and systemic inflammation compared to when a bacterial pathogen is absent.
48. Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005; 172:85-91. This study demonstrated that strains of H. influenzae isolated during exacerbations induce more airway inflammation and are likely to have different virulence capabilities compared to strains isolated during asymptomatic colonization.
49. Watanabe T, Jono H, Han J, et al. Synergistic activation of NF-kappaB by nontypeable Haemophilus influenzae and tumor necrosis factor alpha. Proc Natl Acad Sci U S A 2004; 101:3563-3568.
50. Ratner AJ, Lysenko ES, Paul MN, Weiser JN. Synergistic proinflammatory responses induced by polymicrobial colonization of epithelial surfaces. Proc Natl Acad Sci U S A 2005; 102:3429-3434. H. influenzae and S. pneumoniae showed a synergistic effect in inducing IL-8 through an NFκB-dependent mechanism in an in vitro cell culture model and in a mouse model.
51. Mikami F, Gu H, Jono H, et al. Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via an Src-dependent p38 mitogen-activated protein kinase signaling pathway. J Biol Chem 2005; 280:36185-36194. Epidermal growth factor receptor is a negative regulator of TLR2 induction during bacterial infection. Epidermal growth factor increases invasion of H. influenzae of epithelial cells, providing biological significance of this TLR2 regulation.